CA Patent

CA2423568A1 — Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same

Assigned to Kissei Pharmaceutical Co Ltd · Expires 2002-04-11 · 24y expired

What this patent protects

Glucopyranosyloxybenzylbenzene derivatives represented by the following general formula (I) which have an improved oral absorbability, exert an excellent effect of inhibiting human SGLT2 activity in vivo and, therefore, are useful as preventives or remedies for diseases caused by…

USPTO Abstract

Glucopyranosyloxybenzylbenzene derivatives represented by the following general formula (I) which have an improved oral absorbability, exert an excellent effect of inhibiting human SGLT2 activity in vivo and, therefore, are useful as preventives or remedies for diseases caused by hyperglycemia such as diabetes, complication of diabetes and obesity wherein P represents a group constituting a prodrug; and R represents lower alkyl, lower alkoxy, lower alkylthio, lower alkoxy lower alkyl, lower alkoxy lower alkoxy or lowe r alkoxy lower alkylthio.

Drugs covered by this patent

Patent Metadata

Patent number
CA2423568A1
Jurisdiction
CA
Classification
Expires
2002-04-11
Drug substance claim
No
Drug product claim
No
Assignee
Kissei Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.